Dr. David Gould joined Merlin Nexus in 2003. He spent 1998 to 2002 as a Vice President at Dresdner Kleinwort Capital, where he was part of a transatlantic life sciences team, managing private and public investments in the U.S. and Europe. His responsibilities included working on all aspects of biotechnology and medical device investments, including sourcing/screening, due diligence, execution, monitoring/board observation, and exiting. In 2003 he received his MBA in Finance from Stern School of Business, New York University. In 1998, Dr. Gould received his M.D. from Jefferson Medical College in Philadelphia, Pennsylvania. In 1993, he received a B.S. in Molecular Biology from the University of Wisconsin—Madison. Dominique Sémon joined Merlin Nexus in 2001 as Private Equity Chief Investment Officer. Mr. Sémon started his career in 1983 at Biogen in Geneva, Switzerland, where he created and managed the company’s DNA sequencing laboratory. While at Biogen he participated in various R&D projects, including hepatitis B vaccine, beta interferon and tumor necrosis factor and has written numerous articles that have appeared in well recognized scientific publications. In 1989, he joined Citibank Global Asset Management in Zurich, Switzerland as a management trainee and served in various management positions in Zurich and New York until 1992. From 1992 to 1998, Mr. Sémon managed a healthcare private equity portfolio at New York Life Insurance Company, where his responsibilities included all aspects of private equity investing. From early 1998 until March 2001, Mr. Sémon was Head of Health Care Private Capital Markets Group at Robertson Stephens, a leading investment bank, where he had responsibility for all aspects of private placement transactions, including origination, due diligence, and marketing. Over a three year period, he raised over $1 billion of capital in more than 20 transactions, including sale of preferred stock and PIPE offerings to the U.S. and European institutional market. Mr. Sémon holds a License ès Science in Molecular Biology from the University of Neuchatel, Switzerland and a M.A. in Economics from New York University. He is a Chartered Financial Analyst (CFA).
If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.